Research Topics
| P A MeyersSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern eraTrang H La
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 64:544-50. 2006..The presence of metastases at diagnosis is a predictive factor not only for death but also for local failure...
Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrierRui Yang
Department of Pediatrics and Molecular Pharmacology R, Y, R, G, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY 10461, USA
BMC Cancer 8:124. 2008..Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied...- High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosisP A Meyers
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 19:2812-20. 2001.... - Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexatePaul A Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:2004-11. 2005.... - High-dose therapy with autologous stem cell rescue for pediatric sarcomasPaul A Meyers
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Opin Oncol 16:120-5. 2004..This review evaluates the results of high dose therapy with stem cell reconstitution used to consolidate treatment of high risk patients with sarcomas... - Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adultsE Anders Kolb
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, PO Box 139, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 21:3423-30. 2003..To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy... 
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology GroupPaul A Meyers
Children s Oncology Group, Arcadia, CA, USA
J Clin Oncol 26:633-8. 2008..To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma...- Muramyl tripeptide (mifamurtide) for the treatment of osteosarcomaPaul A Meyers
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Expert Rev Anticancer Ther 9:1035-49. 2009..Mifamurtide has been approved in Europe for the treatment of newly diagnosed osteosarcoma in combination with chemotherapy... - Addition of pamidronate to chemotherapy for the treatment of osteosarcomaPaul A Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 117:1736-44. 2011..This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma... - Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocolP A Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 16:2452-8. 1998..The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS... - High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumorsB H Kushner
Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 16:3016-20. 1998..To help fill the gap in knowledge about the risk of leukemia from repetitive high-dose use of alkylating agents and topoisomerase-II inhibitors in young patients with solid tumors... - The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcomaJ S Wunder
Department of Surgery, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York City, NY 10021, USA
J Bone Joint Surg Am 80:1020-33. 1998..These indicators should be used to identify patients who are at high risk for metastasis as such patients may be candidates for more intensive or novel therapies... - How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature reviewB H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 19:870-80. 2001..We now present results achieved with that approach, as carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) and as reported in the literature... - The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experienceSusan N Chi
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Pediatr Blood Cancer 42:46-51. 2004..This limited single institutional experience can be explored further in the context of a multi-institutional effort... - Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology GroupSmita Bhatia
Division of Pediatric Oncology, City of Hope National Medical Center, Duarte, CA, USA
Blood 109:46-51. 2007..Increasing exposure to ifosfamide from 90 to 140 g/m2, cyclophosphamide from 9.6 to 17.6 g/m2, and doxorubicin from 375 to 450 mg/m2 increased the risk of t-MDS/AML significantly... - Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupAlexander J Chou
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer 115:5339-48. 2009..The authors report the results of addition of liposomal MTP-PE to chemotherapy for patients with metastatic OS... - Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcomaR Gorlick
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Clin Cancer Res 7:3065-70. 2001..99m)Tc-MIBI imaging did not correlate with measures of P-glycoprotein expression in the tumor tissue... - Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumorsB H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Pediatr Oncol 35:468-74. 2000..We tested the hypothesis that much higher dosing would meet critical goals of salvage therapy: antitumor effect and a lack of toxicity to key organs, so as not to preclude subsequent consolidative treatments needed for cure... - Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemiaPeter G Steinherz
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Pediatr Hematol Oncol 29:656-8. 2007..The remissions were sustained with repeated cycles of monotherapy for 47, 59, and 64 weeks, respectively... - Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcomaLeLe Aung
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:342-8. 2003..This implies that principles used in treatment of primary OS may be applied to patients with late metachronous skeletal OS... - Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcomaSuzanne L Wolden
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, SM07, New York, NY 10021, USA
Cancer 97:179-85. 2003..The authors evaluated the outcome of patients with rhabdomyosarcoma (RMS) who were treated with three-dimensional (3D) conformal radiation therapy (RT) at a single institution... - Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specificRichard Gorlick
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Pediatr Hematol Oncol 25:840-1. 2003 - Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcomaSuzanne L Wolden
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Radiat Oncol Biol Phys 61:1432-8. 2005..To determine the preliminary results of intensity-modulated radiotherapy (IMRT) for head-and-neck rhabdomyosarcoma... - Ewing's sarcoma in a patient with congenital optic atrophyC Fein Levy
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Pediatr Hematol Oncol 20:577-9. 1998..However, she continues to have deterioration of her visual acuity. CONCLUSION: This report of cancer in a child with dominant optic atrophy suggests the possible need for a higher degree of suspicion of malignancy in these patients... - Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experienceAlexander J Chou
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:2214-21. 2005..Patients appeared to benefit from the addition of ifosfamide to their retrieval regimens. In the end, the role of chemotherapy in recurrent OS continues to remain undefined... - Methotrexate levels and outcome in osteosarcomaShayna Zelcer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Pediatr Blood Cancer 44:638-42. 2005..The significant degree of intra-patient variability in peak levels poses a dilemma for pharmacokinetic adjustment. Continued use of HD-MTX in all patients, rather than dose adapted therapy, may be justified... - Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemiaP A Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021
Cancer 64:2416-9. 1989..Although AZQ and AAFC are active in childhood ANLL with acceptable toxicity, the combination does not appear more active than AZQ used alone. Future studies should define the role of AZQ in combination with other agents... - Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcomaCaroline Laverdiere
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 98:832-40. 2003..CONCLUSIONS: ET-743 was found to be well tolerated in heavily pretreated osteosarcoma patients but had limited antitumor activity as a single agent. The combination of ET-743 with cisplatin or doxorubicin should be considered... - Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experienceMaura Cosetti
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
J Pediatr Hematol Oncol 24:101-5. 2002..with minimal hematopoietic toxicity, making it ideal for further evaluation in patients at high risk with newly diagnosed disease, particularly in combination with other active agents with nonoverlapping toxicities... - Leydig cell tumor after treatment for Ewing's sarcomaLinda J Butros
Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
Pediatr Blood Cancer 49:1008-10. 2007..Additional monitoring for second malignancies may become appropriate as long-term survival continues to improve for patients with Ewing's sarcoma... - Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcomaBang H Hoang
Department of Surgery, Orthopaedic Surgery Service, affiliated with Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Cancer 109:106-11. 2004..These results showed that expression of LRP5 is a common event in OS and strongly suggest a role for LRP and Wnt signaling in the pathobiology and progression of this disease... - Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcomaHeather Magnan
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer 116:4147-51. 2010..In the current study, the authors re-examined a series of patients studied using Tl-201 scintigraphy to determine the correlation between changes observed on Tl-201 scintigraphy and event-free survival (EFS)... - Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experienceDenise A Casey
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Pediatr Blood Cancer 53:1029-34. 2009..A pediatric phase I trial has shown this regimen to be safe and active in advanced ES... - Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samplesRui Yang
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 9:837-44. 2003..Additional studies are under way to determine the clinical significance of these sequence alterations and their effect on methotrexate transport and resistance... - Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcomaRui Yang
Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY, USA
Int J Cancer 121:943-54. 2007..This study suggests that PTHR1 over-expression may promote osteosarcoma progression by conferring a more aggressive phenotype, and forming a more favorable microenvironment... - mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcomaRebecca Sowers
Department of Pediatrics, Orthopaedic Surgery Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Mol Cancer Ther 2:535-41. 2003.... - The challenging role of radiation therapy for very young children with rhabdomyosarcomaDev R Puri
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 65:1177-84. 2006..Local control may be maximized when EBRT begins <or=18 weeks after initiation of CMT, but further study is warranted. Longer follow-up is required to determine the full extent of late effects... - Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcomaTadahiko Kubo
Orthopedic Surgery Service, Memorial Sloan Kettering Cancer Center, Weil Medical College of Cornell University, New York, New York, USA
Cancer 112:2119-29. 2008.... - PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging toolsMichelle L Klem
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Pediatr Hematol Oncol 29:9-14. 2007..Complete staging of rhabdomyosarcoma is critical to deliver appropriate therapy. We evaluated the role of F-fluorodeoxyglucose positron emission tomography (PET) in the staging of patients with rhabdomyosarcoma... - Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imagingJonathan P Dyke
Department of Radiology, Weill Medical College of Cornell University, 1300 York Ave, Box 234, New York, NY 10021 4885, USA
Radiology 228:271-8. 2003..The ability to determine response to induction chemotherapy by means of noninvasive monitoring of necrotic fraction with perfusion MR imaging methods may provide useful prognostic information and help surgical planning... - Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center ExperienceLeLe Aung
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 95:1728-34. 2002..Although additional follow-up is warranted, the successes of current treatment regimens consisting of intensive, high-dose chemotherapy in combination with topoisomerase II inhibitors outweigh the risks... - Radiotherapy in the multimodal treatment of extrarenal extracranial malignant rhabdoid tumorsDev R Puri
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Pediatr Blood Cancer 50:167-9. 2008..Our limited experience suggests that RT in the setting of CMT and surgery has the potential to prolong survival with acceptable toxicity, but outcomes are inconsistent and further study is necessary... - Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcomaCaroline Laverdiere
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 11:2561-7. 2005..To determine if osteosarcoma cells express chemokine receptors and if their presence or absence relates to clinical features... - Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathwayBang H Hoang
Department of Surgery, Orthopaedic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer Res 64:2734-9. 2004..Taken together, these results support a possible role for Wnt signaling in the pathobiology and progression of human OS... - Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcomaChing C Lau
Department of Pediatrics, Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
Genes Chromosomes Cancer 39:11-21. 2004.... - Primary desmoplastic small round cell tumor of the femurAkihiko Yoshida
Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Skeletal Radiol 37:857-62. 2008..This is the second reported case of primary DSRCT of bone with genetic confirmation... - Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor studyJill P Ginsberg
Division of Oncology, Department of Pediatrics, The Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Colket Translational Research Bldg, 3501 Civic Center Blvd, 10th Floor, Philadelphia, PA 19104, USA
J Natl Cancer Inst 102:1272-83. 2010..The survival of Ewing sarcoma (ES) patients has improved since the 1970s but is associated with considerable future health risks... - The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescueShayna Zelcer
Department of Pediatrics, Division of Hematology Oncology, Children s Hospital of Western Ontario, London, Ontario, Canada
Pediatr Blood Cancer 50:1176-80. 2008..We describe the safety and feasibility of an outpatient high dose methotrexate (HDMTX) regimen... - An expression signature classifies chemotherapy-resistant pediatric osteosarcomaMichelle B Mintz
Neurogenomics Division and Genetic Basis of Human Disease Division, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA
Cancer Res 65:1748-54. 2005..We propose that osteosarcoma tumor-driven changes in the bone microenvironment contribute to the chemotherapy-resistant phenotype and offer testable hypotheses to potentially enhance therapeutic response... - Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of boneHolcombe E Grier
Department of Pediatric Hematology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
N Engl J Med 348:694-701. 2003..We designed a study to test whether the addition of these drugs to a standard regimen would improve the survival of patients with newly diagnosed disease... - Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group studyJames S Miser
City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
J Clin Oncol 22:2873-6. 2004.... - High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remissionNeyssa Marina
J Clin Oncol 23:4262-4. 2005 - Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasisSaminathan S Nathan
Department of Orthopaedics, Faculty of Medicine, National University of Singapore, Singapore, USA
Cancer 107:1607-16. 2006..A treatment strategy emphasizing clinical remission at all identifiable sites offers the highest likelihood of survival in this patient population... - Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943Nita L Seibel
Hematology Oncology, Children s National Medical Center, George Washington University School of Medicine, Washington, DC 20010, USA
Cancer 109:1646-53. 2007.... - The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolateRui Yang
Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, New York 10467, USA
Clin Cancer Res 13:2557-67. 2007..Although defective RFC-mediated transport was frequently identified as a mechanism of methotrexate (MTX) resistance in osteosarcoma, the status of FR and its role in this disease are unknown... - Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology GroupJames S Miser
Division of Pediatrics, Department of Pediatric Hematology Oncology, City of Hope National Medical Center, Duarte, California 91010, USA
Pediatr Blood Cancer 49:894-900. 2007..We evaluated whether a dose-intensity chemotherapy regimen improved survival for patients with ESFTs of bone with metastases at diagnosis... - Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology GroupMark L Bernstein
Hopital Sainte Justine, Hematology Oncology, Montreal Quebec, Canada
J Clin Oncol 24:152-9. 2006..We studied topotecan alone and combined with cyclophosphamide in therapeutic windows before the five-drug therapy. A randomly assigned proportion of patients received amifostine as a cytoprotective agent... - Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administrationJaime Morales-Arias
Division of Pediatrics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 110:1568-77. 2007..Whether ES cells and patient tumor samples express G-CSF and its receptor (G-CSFR) and whether treatment with this factor enhances tumor growth was examined... - Loss of antibody titers and effectiveness of revaccination in post-chemotherapy pediatric sarcoma patientsJennifer Yu
Robert Wood Johnson Medical School, Piscataway, New Jersey, USA
Pediatr Blood Cancer 49:656-60. 2007..Little is known about the effects of chemotherapy on patient antibody titers to vaccine-preventable infectious diseases; thus, there is no standard protocol for revaccinating post-chemotherapy patients...